Everything below concerns dual agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
=== Skin injections in plastic surgery === Sodium hyaluronate is injected to reduce wrinkles on the face. As of 2017, the FDA had approved 13 hyaluronate preparations as so called dermal fillers. They are also used as a filler of lips or in other parts of the body, though not FDA approved. The filling effect is temporary and lasts for about six months or longer in most people.
== Helicity (polarization) of neutrinos, electrons and positrons emitted in beta decay == After the discovery of parity non-conservation (see § History), it was found that, in beta decay, electrons are emitted mostly with negative helicity, i.e., they move, naively speaking, like left-handed screws driven into a material (they have negative longitudinal polarization). Conversely, positrons have mostly positive helicity, i.e., they move like right-handed screws. Neutrinos (emitted in positron decay) have negative helicity, while antineutrinos (emitted in electron decay) have positive helicity. The higher the velocity (energy) of the particles, the higher their helicity polarization; this reflects the absolute chirality selection in W boson decay.
==== Serbia ==== Taco Bell opened its first store in Serbia, in the capital city of Belgrade, on November 20, 2025, at the Ušće Shopping Center. Serbia is the second country of the former Yugoslavia in which Taco Bell is present. Second opened in Novi Sad.
Sources: en.wikipedia.org
=== Collection of data from phylogenetic trees === For each branch in the phylogenetic trees of the protein families, the number of mismatches that were observed were recorded and a record kept of the two amino acids involved. These counts were used as entries below the main diagonal of the matrix
=== Familia Rotary/R100 === In July 1968 Mazda added a Familia Rotary model to the range, offered in both two-door coupé and four-door saloon variants. Saloon models were given an additional "SS" nameplate. The Familia Rotary was powered by a 982 cc 10A Wankel rotary engine and the coupé version was sold outside Japan as the "Mazda R100". After an April 1970 update (known colloquially in Australia as the Series 2) it was known as the "Familia Presto Rotary" in Japan as the Presto nameplate was added into the entire Familia range. Power was rated at just 100 PS (74 kW) due to a small carburetor (thus the "R100" name). The rotary engined R100 has a unique front end design, with a more prominent pointed bonnet, grille, and bumper. The rear also gained its own design with twin round tail lights, which became for a time a signature design element for the rotary engined versions of Mazda's cars. Inside, the cars were more sumptuously appointed with plusher seats and chrome plated accents, full sized interior door trim panels, a floor mounted handbrake lever, and a unique cockpit styled dashboard with full instrumentation. Mazda referred to this dashboard as the "T-Dash", and fitted it to top spec piston engined variants of the Familia on the Japanese market as well as the rotary models.
== Further reading == Aida, N.; Tamagawa, K.; Takada, K.; Yagishita, A.; Kobayashi, N.; Chikumaru, K.; Iwamoto, H. (April 1996). "Brain MR in Fukuyama congenital muscular dystrophy". American Journal of Neuroradiology. 17 (4): 605–613. PMC 8337276. PMID 8730178. Saito, Fumiaki; Matsumura, Kiichiro (December 2011). "Fukuyama-type congenital muscular dystrophy and defective glycosylation of α-dystroglycan". Skeletal Muscle. 1 (1): 22. doi:10.1186/2044-5040-1-22. PMC 3156645. Fukuyama type muscular dystrophy at NIH's Office of Rare Diseases
== Re-activity (1980–2000) == In 1980, old friend (and fellow ex-Sinner) Dave Machan persuaded Ron to perform again, along with vocalist Kathy Monaco this time in a folk based group called Trinity (Ron played bass for this group). Trinity recorded an albums' worth of material at Dayson Studios (owned by George Day and also home to much of the work done by Ron Wray for the History of Syracuse Music releases) which still remains unreleased. Though Trinity was successful on the nightclub scene, Ron wanted to return to the rock music that was his first love, and tried to re-form The Saint and the Sinners which soon changed their name to East Side Story (later East Side). East Side specialized in classic oldies and seventies hard rock. This band lasted (with virtually the same line-up) for fifteen years before folding in 2000. Some of the members of East Side were Graham Daniels (1984–2000), Larry Brennan (1984–2000), Tom DiRenzo (1988–2000), John Mirra (1991–1993; 1997–2000), Earl "the Pearl" Hamilton (formerly of The New York Flyers now with Redline (1994–1997), Dave Machan (1984–1987) and Barry Glisker (1984–1989).
Sources: en.wikipedia.org
It is usually well tolerated, though overdose toxicity is possible. Occasionally side effects include headache, numbness, and sleepiness. Pyridoxine overdose can cause a peripheral sensory neuropathy characterized by poor coordination, numbness, and decreased sensation to touch, temperature, and vibration. Healthy human blood levels of pyridoxine are 2.1–21.7 ng/mL. Normal doses are safe during pregnancy and breastfeeding.
=== Israel trip === During a July 2026 trip to Israel, Chabad "outreach figure" Yossi Farro presented Peters with a "custom necklace" which shows the Star of David fused with the OpenAI logo. The moment was considered the "latest flashpoint" in a debate over how the Jewish community should engage with controversial online figures. Farro joked online that the "mashup" amounted to the AI company's logo "mogging" the Jewish star. The two switched restaurants mid-meal once Peters realized the one they had chosen was not kosher. Farro posted about the trip, saying Peters "is loving Israel and Israel is loving him." "Peters's manager is Jewish," Farro further explained, "and the rabbi of the Chabad community connected to the manager thought it would be worthwhile to introduce us. Thank God, we connected." The Times of Israel reported that Peters had been seen talking to prime minister Benjamin Netanyahu's adviser Topaz Luk at a Tel Aviv nightclub. Israeli influencers who appeared on Peters's streams, Shira Braun and Shira Klein, were reprimanded and demoted from their positions by the Israel Defense Forces.
The biosynthetic pathway of nicotine involves a coupling reaction between the two cyclic structures that comprise nicotine. Metabolic studies show that the pyridine ring of nicotine is derived from nicotinic acid, while the pyrrolidine is derived from N-methyl-Δ1-pyrrollidium cation. Biosynthesis of the two component structures proceeds via two independent syntheses, the NAD pathway for nicotinic acid and the tropane pathway for N-methyl-Δ1-pyrrollidium cation. The NAD pathway in the genus Nicotiana begins with the oxidation of aspartic acid into α-amino succinate by aspartate oxidase (AO). This is followed by a condensation with glyceraldehyde-3-phosphate and a cyclization catalyzed by quinolinate synthase (QS) to give quinolinic acid. Quinolinic acid then reacts with phosphoribosyl pyrophosphate catalyzed by quinolinic acid phosphoribosyl transferase (QPT) to form nicotinic acid mononucleotide (NaMN). The reaction now proceeds via the NAD salvage cycle to produce nicotinic acid via the conversion of nicotinamide by the enzyme nicotinamidase. The N-methyl-Δ1-pyrrollidium cation used in the synthesis of nicotine is an intermediate in the synthesis of tropane-derived alkaloids. Biosynthesis begins with decarboxylation of ornithine by ornithine decarboxylase (ODC) to produce putrescine. Putrescine is then converted into N-methyl putrescine via methylation by SAM catalyzed by putrescine N-methyltransferase (PMT).
=== By training === If individuals are asked to estimate their BAC, then given accurate feedback via a breathalyzer, and this procedure is repeated a number of times during a drinking session, studies show that these individuals can learn to discriminate their BAC, to within a mean error of 9 mg/100 mL (0.009% BAC). The ability is robust to different types of alcohol, different drink quantities, and drinks with unknown levels of alcohol. Trained individuals can even drink alcoholic drinks so as to adjust or maintain their BAC at a desired level. Training the ability does not appear to require any information or procedure besides breathalyzer feedback, although most studies have provided information such as intoxication symptoms at different BAC levels. Subjects continue to retain the ability one month after training.
Dipeptides are white solids. Many are far more water-soluble than the parent amino acids. For example, the dipeptide Ala-Gln has the solubility of 586 g/L more than 10x the solubility of Gln (35 g/L). Dipeptides also can exhibit different stabilities, e.g. with respect to hydrolysis. Gln does not withstand sterilization procedures, whereas this dipeptide does. Because dipeptides are prone to hydrolysis, the high solubility is exploited in infusions, i.e. to provide nutrition.
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.